Fragmento

Article commented: Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptoralpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology 2016; 150: 1147-59. Comment: Nonalcoholic steatohepatitis (NASH), the severe histological form of nonalcoholic fatty liver disease (NAFLD), is a chronic liver disease that has been neglected in the past but fortunately, is currently given full attention not only by health care providers but scientist involved in pharmacological research. This is justified by both, the alarming increasing disease prevalence and the knowledge gained from its natural history that may eventually end in liver cirrhosis and the development of hepatocellular carcinoma.

Palabras clave:

2016-06-23   |   406 visitas   |   Evalua este artículo 0 valoraciones

Vol. 15 Núm.4. Julio-Agosto 2016 Pags. 604-609 Ann Hepatol 2016; 15(4)